Discover a study where patients reported a high severity of treatment side effects than anticipated by their clinicians.

Join leading experts to discuss how we are ushering in a new era in bladder cancer care on May 28 virtually. Register now.

Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK ...

Colorectal cancer is on the rise among young adults. An international research effort led by UC San Diego bioengineers has uncovered that DNA mutations arising during early childhood from a bacterial ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

AUA annual meeting featured the 4 th annual IBCG Bladder Cancer Forum evaluating common problems and controversies in bladder ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

In a study from Dr. Zlotta’s group published in 2025 in the Journal of Urology, 1 they suggest that better tools are needed to minimize interobserver variability in pathological grading. This is ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management ...

Among patients with non-muscle-invasive bladder cancer (NMIBC), neoadjuvant treatment with mitomycin C prior to transurethral ...